Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($1.24), $0.44 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $37.66 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.